Hayashi M, Matsunaga K, Okahara A, Mita S
Central Research Laboratories, Santen Pharmaceutical Co. Ltd., Osaka, Japan.
J Rheumatol. 1991 May;18(5):691-5.
The effects of bucillamine, a new antirheumatic drug, on type II collagen induced arthritis in rats was examined. Bucillamine inhibited hindpaw swelling in a dose dependent manner. The histopathological study indicated that bucillamine inhibited the proliferation of synovial lining cells. The anti-type II collagen antibody level was also decreased by the treatment with bucillamine. D-penicillamine, on the other hand, showed no beneficial effects on arthritis except for inhibiting new bone formation. Our findings suggest that bucillamine has beneficial effects on type II collagen induced arthritis in rats and that its mechanism of action is different from those of D-penicillamine.
研究了新型抗风湿药物布西拉明对大鼠Ⅱ型胶原诱导性关节炎的影响。布西拉明以剂量依赖的方式抑制后爪肿胀。组织病理学研究表明,布西拉明抑制滑膜衬里细胞的增殖。用布西拉明治疗也可降低抗Ⅱ型胶原抗体水平。另一方面,D-青霉胺除了抑制新骨形成外,对关节炎没有有益作用。我们的研究结果表明,布西拉明对大鼠Ⅱ型胶原诱导性关节炎有有益作用,其作用机制与D-青霉胺不同。